口服P2Y12抑制剂预处理对非ST段抬高型急性冠脉综合征患者心血管与出血结局的影响:系统评价与Meta分析
该系统评价与Meta分析纳入7项随机临床试验、13226例接受侵入性策略的NSTEACS患者(预处理组6603例 vs 无预处理组6623例),比较造影前口服P2Y12抑制剂预处理与明确冠脉解剖后给药。结果显示预处理与30天MACE(OR 0.95;95%CI 0.78-1.15;I²=28%)、30天心梗(OR 0.90;95%CI 0.72-1.12;I²=19%)及30天心血管死亡(OR 0.79;95%CI 0.49-1.27;I²=0%)无显著关联,但30天大出血风险增加(OR 1.51;95%CI 1.16-1.97;I²=41%),致1例大出血的伤害需治疗人数为63例。作者结论认为该研究不支持对接受早期侵入性策略的NSTEACS患者常规进行口服P2Y12抑制剂预处理。
要点
- 在NSTEACS接受侵入性策略的患者中,造影前口服P2Y12抑制剂预处理与30天MACE无显著关联(OR 0.95;95%CI 0.78-1.15;I²=28%)。
- 预处理与30天心梗(OR 0.90;95%CI 0.72-1.12;I²=19%)和30天心血管死亡(OR 0.79;95%CI 0.49-1.27;I²=0%)均无显著关联。
- 预处理组30天大出血风险增加(OR 1.51;95%CI 1.16-1.97;I²=41%),每63例预处理导致1例大出血。
- 作者结论认为,该研究不支持对接受早期侵入性策略的NSTEACS患者常规行口服P2Y12抑制剂预处理。
- 纳入7项随机临床试验共13226例患者,其中非ST段抬高型心梗7430例(61.7%),经桡动脉入路4295例(32.6%),接受PCI 10945例(82.8%)。
适用人群与场景
- 接受侵入性策略的非ST段抬高型急性冠脉综合征(NSTEACS)患者,纳入7项随机临床试验共13226例,预处理组6603例、无预处理组6623例。
- 患者平均年龄64岁,女性3598例(27.2%);非ST段抬高型心梗7430例(61.7%),经桡动脉入路4295例(32.6%),接受经皮冠状动脉介入治疗10945例(82.8%)。
诊断标准与关键阈值
- 预处理定义为造影前给予口服P2Y12抑制剂;无预处理定义为造影后、明确冠状动脉解剖时给药。
研究设计与关键结果
- 系统评价与Meta分析纳入7项随机临床试验、13226例NSTEACS患者,比较造影前口服P2Y12抑制剂预处理(6603例)与明确冠脉解剖后给药(6623例)。
- 预处理与30天MACE无显著关联(OR 0.95;95%CI 0.78-1.15;I²=28%)。
- 预处理与30天心肌梗死无显著关联(OR 0.90;95%CI 0.72-1.12;I²=19%)。
- 预处理与30天心血管死亡无显著关联(OR 0.79;95%CI 0.49-1.27;I²=0%)。
- 预处理组30天大出血风险增加(OR 1.51;95%CI 1.16-1.97;I²=41%)。
- 口服P2Y12抑制剂预处理导致1例大出血的伤害需治疗人数为63例。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入7项随机临床试验。
- 检索数据库包括PubMed、MEDLINE、Embase、Scopus、Web of Science、Science Direct、clinicaltrials.gov和Cochrane Central Register for Controlled Trials,检索时间自数据库建库至2021年3月20日。
- 采用随机效应模型,并按P2Y12抑制剂类型、血运重建策略和入路部位进行分层分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,该研究不支持对接受早期侵入性策略的NSTEACS患者常规行口服P2Y12抑制剂预处理。
- 预处理与30天MACE、心梗及心血管死亡无显著关联,但大出血风险增加(OR 1.51;95%CI 1.16-1.97)。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The practice of pretreatment with oral P2Y12 inhibitors in non-ST elevation acute coronary syndromes (NSTEACS) remains common; however, its association with improved cardiovascular outcomes is unclear.
OBJECTIVE: To assess the association between oral P2Y12 inhibitor pretreatment and cardiovascular and bleeding outcomes in patients with NSTEACS.
DATA SOURCES: On March 20, 2021, PubMed, MEDLINE, Embase, Scopus, Web of Science, Science Direct, clinicaltrials.gov, and the Cochrane Central Register for Controlled Trials were searched from database inception.
STUDY SELECTION: Randomized clinical trials of patients with NSTEACS randomized to either oral P2Y12 inhibitor pretreatment (defined as prior to angiography) or no pretreatment (defined as following angiography, once coronary anatomy was known) among patients undergoing an invasive strategy.
DATA EXTRACTION AND SYNTHESIS: This study followed Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Data on publication year, sample size, clinical characteristics, revascularization strategy, P2Y12 inhibitor type and dosage, time from pretreatment to angiography, and end point data were independently extracted by 2 authors. A random-effects model was used, including stratification by (1) P2Y12 inhibitor type, (2) revascularization strategy, and (3) access site.
MAIN OUTCOMES AND MEASURES: The primary end point was 30-day major adverse cardiac events (MACEs). Secondary end points were 30-day myocardial infarction (MI) and cardiovascular death. The primary safety end point was 30-day major bleeding (defined according to individual studies).
RESULTS: A total of 7 trials randomizing 13 226 patients to either pretreatment (6603 patients) or no pretreatment (6623 patients) were included. The mean age of patients was 64 years and 3598 (27.2%) were female individuals. Indication for P2Y12 inhibitors was non-ST elevation myocardial infarction in 7430 patients (61.7%), radial access was used in 4295 (32.6%), and 10 945 (82.8%) underwent percutaneous coronary intervention. Pretreatment was not associated with a reduction in 30-day MACE (odds ratio [OR], 0.95; 95% CI, 0.78-1.15; I2 = 28%), 30-day MI (OR, 0.90; 95% CI, 0.72-1.12; I2 = 19%), or 30-day cardiovascular death (OR, 0.79; 95% CI, 0.49-1.27; I2 = 0%). The risk of 30-day major bleeding was increased among patients who underwent pretreatment (OR, 1.51; 95% CI, 1.16-1.97; I2 = 41%). The number needed to harm to bring about 1 major bleeding event with oral P2Y12 inhibitor pretreatment was 63 patients.
CONCLUSIONS AND RELEVANCE: In this study, pretreatment with oral P2Y12 inhibitors among patients with NSTEACS prior to angiography, compared with treatment once coronary anatomy is known, was associated with increased bleeding risk and no difference in cardiovascular outcomes. Routine pretreatment with oral P2Y12 inhibitors in patients with NSTEACS receiving an early invasive strategy is not supported by this study.
参考来源
- Dawson LP, Chen D, Dagan M, et al. Assessment of Pretreatment With Oral P2Y12 Inhibitors and Cardiovascular and Bleeding Outcomes in Patients With Non-ST Elevation Acute Coronary Syndromes: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021. PMID: 34797371. doi:10.1001/jamanetworkopen.2021.34322
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。